# Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia Patients

> **NCT04572685** · PHASE1 · COMPLETED · sponsor: **Luye Pharma Group Ltd.** · enrollment: 36 (actual)

## Conditions studied

- Schizophrenia Patients

## Interventions

- **DRUG:** Paliperidone Palmitate

## Key facts

- **NCT ID:** NCT04572685
- **Lead sponsor:** Luye Pharma Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-22
- **Primary completion:** 2020-06-26
- **Final completion:** 2020-08-20
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2020-11-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04572685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04572685, "Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04572685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*